Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) Sees Large Drop in Short Interest

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA – Get Rating) was the target of a significant drop in short interest in the month of February. As of February 15th, there was short interest totalling 831,100 shares, a drop of 8.3% from the January 31st total of 905,900 shares. Based on an average daily volume of 731,200 shares, the short-interest ratio is currently 1.1 days. Currently, 1.1% of the shares of the company are sold short.

Analysts Set New Price Targets

A number of equities analysts recently commented on the company. Brookline Capital Management reiterated a “buy” rating on shares of Hepion Pharmaceuticals in a report on Tuesday, January 31st. Alliance Global Partners initiated coverage on shares of Hepion Pharmaceuticals in a research report on Monday, January 23rd. They issued a “buy” rating for the company.

Institutional Investors Weigh In On Hepion Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in HEPA. Envestnet Asset Management Inc. raised its position in shares of Hepion Pharmaceuticals by 131.9% in the fourth quarter. Envestnet Asset Management Inc. now owns 202,978 shares of the company’s stock valued at $61,000 after buying an additional 115,437 shares in the last quarter. Renaissance Technologies LLC raised its position in Hepion Pharmaceuticals by 85.3% during the second quarter. Renaissance Technologies LLC now owns 234,600 shares of the company’s stock valued at $134,000 after purchasing an additional 108,000 shares in the last quarter. PVG Asset Management Corp acquired a new position in Hepion Pharmaceuticals during the third quarter valued at approximately $55,000. Virtu Financial LLC raised its position in Hepion Pharmaceuticals by 195.6% during the third quarter. Virtu Financial LLC now owns 67,802 shares of the company’s stock valued at $34,000 after purchasing an additional 44,867 shares in the last quarter. Finally, State Street Corp raised its position in Hepion Pharmaceuticals by 8.1% during the first quarter. State Street Corp now owns 348,910 shares of the company’s stock valued at $450,000 after purchasing an additional 26,194 shares in the last quarter. 9.37% of the stock is currently owned by institutional investors and hedge funds.

Hepion Pharmaceuticals Trading Down 4.9 %

NASDAQ HEPA opened at $0.83 on Tuesday. Hepion Pharmaceuticals has a 1-year low of $0.26 and a 1-year high of $1.33. The company has a 50 day moving average of $0.70 and a 200-day moving average of $0.56. The company has a market cap of $62.90 million, a price-to-earnings ratio of -1.40 and a beta of 1.64.

About Hepion Pharmaceuticals

(Get Rating)

Hepion Pharmaceuticals, Inc is a biopharmaceutical company, which engages in the development of drug therapy for treatment of chronic liver diseases. It focuses on the development of its product candidate CRV431, a cyclophilin inhibitor that targets biochemical pathways involved in the progression of liver disease.